USRE42645E1 - Nutritional or therapeutic compositions and methods to increase bodily glutathione levels - Google Patents
Nutritional or therapeutic compositions and methods to increase bodily glutathione levels Download PDFInfo
- Publication number
- USRE42645E1 USRE42645E1 US11/371,804 US37180406A USRE42645E US RE42645 E1 USRE42645 E1 US RE42645E1 US 37180406 A US37180406 A US 37180406A US RE42645 E USRE42645 E US RE42645E
- Authority
- US
- United States
- Prior art keywords
- composition
- selenium
- glutathione
- mammal
- cystine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 title claims abstract description 82
- 239000000203 mixture Substances 0.000 title claims abstract description 68
- 108010024636 Glutathione Proteins 0.000 title claims abstract description 40
- 229960003180 glutathione Drugs 0.000 title claims abstract description 40
- 238000000034 method Methods 0.000 title claims abstract description 18
- 235000016709 nutrition Nutrition 0.000 title claims abstract description 5
- 230000001225 therapeutic effect Effects 0.000 title claims abstract description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims abstract description 36
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims abstract description 32
- 229910052711 selenium Inorganic materials 0.000 claims abstract description 27
- 239000011669 selenium Substances 0.000 claims abstract description 27
- 229960003067 cystine Drugs 0.000 claims abstract description 20
- 239000004471 Glycine Substances 0.000 claims abstract description 18
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims abstract description 17
- 239000004220 glutamic acid Substances 0.000 claims abstract description 17
- 235000013922 glutamic acid Nutrition 0.000 claims abstract description 17
- 239000002243 precursor Substances 0.000 claims abstract description 17
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims abstract description 11
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 5
- 241000124008 Mammalia Species 0.000 claims description 20
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 claims description 19
- 150000003839 salts Chemical class 0.000 claims description 16
- 238000011282 treatment Methods 0.000 claims description 13
- 150000008064 anhydrides Chemical class 0.000 claims description 11
- 150000002148 esters Chemical class 0.000 claims description 11
- 241001465754 Metazoa Species 0.000 claims description 8
- -1 mono-seleno Chemical group 0.000 claims description 8
- 231100000252 nontoxic Toxicity 0.000 claims description 8
- 230000003000 nontoxic effect Effects 0.000 claims description 8
- RJFAYQIBOAGBLC-UHFFFAOYSA-N 2-amino-4-methylselanyl-butanoic acid Chemical group C[Se]CCC(N)C(O)=O RJFAYQIBOAGBLC-UHFFFAOYSA-N 0.000 claims description 7
- 239000002253 acid Substances 0.000 claims description 6
- 235000018417 cysteine Nutrition 0.000 claims description 6
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 6
- 125000004432 carbon atom Chemical group C* 0.000 claims description 5
- 230000003197 catalytic effect Effects 0.000 claims description 5
- 230000005965 immune activity Effects 0.000 claims description 5
- 239000012528 membrane Substances 0.000 claims description 5
- 230000001195 anabolic effect Effects 0.000 claims description 3
- PLDSRBDSTIMSQF-UHFFFAOYSA-N methanediselenoic acid Chemical compound [SeH]C=[Se] PLDSRBDSTIMSQF-UHFFFAOYSA-N 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims 2
- JULROCUWKLNBSN-UHFFFAOYSA-N selenocystine Chemical compound OC(=O)C(N)C[Se][Se]CC(N)C(O)=O JULROCUWKLNBSN-UHFFFAOYSA-N 0.000 claims 2
- 239000002552 dosage form Substances 0.000 claims 1
- 230000003834 intracellular effect Effects 0.000 claims 1
- 210000000987 immune system Anatomy 0.000 abstract description 7
- 238000003786 synthesis reaction Methods 0.000 abstract description 2
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 abstract 1
- 239000003826 tablet Substances 0.000 description 15
- 229940065287 selenium compound Drugs 0.000 description 10
- 150000003343 selenium compounds Chemical class 0.000 description 10
- 150000001413 amino acids Chemical class 0.000 description 8
- 235000001014 amino acid Nutrition 0.000 description 7
- 210000004400 mucous membrane Anatomy 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 150000003254 radicals Chemical class 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 210000004379 membrane Anatomy 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 235000021355 Stearic acid Nutrition 0.000 description 3
- 239000006172 buffering agent Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical class OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000008117 stearic acid Substances 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 230000008733 trauma Effects 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 208000034423 Delivery Diseases 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- ZZIFPJZQHRJERU-WDSKDSINSA-N Glu-Cys-Gly Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CS)C(=O)NCC(O)=O ZZIFPJZQHRJERU-WDSKDSINSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical class Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical class OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000007937 lozenge Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- ARIWANIATODDMH-UHFFFAOYSA-N rac-1-monolauroylglycerol Chemical compound CCCCCCCCCCCC(=O)OCC(O)CO ARIWANIATODDMH-UHFFFAOYSA-N 0.000 description 2
- 239000007845 reactive nitrogen species Substances 0.000 description 2
- 239000003642 reactive oxygen metabolite Substances 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000009677 vaginal delivery Effects 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 230000003313 weakening effect Effects 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- FDCJDKXCCYFOCV-UHFFFAOYSA-N 1-hexadecoxyhexadecane Chemical compound CCCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCC FDCJDKXCCYFOCV-UHFFFAOYSA-N 0.000 description 1
- FDKWRPBBCBCIGA-UHFFFAOYSA-N 2-azaniumyl-3-$l^{1}-selanylpropanoate Chemical compound [Se]CC(N)C(O)=O FDKWRPBBCBCIGA-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 1
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000004407 Lactalbumin Human genes 0.000 description 1
- 108090000942 Lactalbumin Proteins 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- RWSXRVCMGQZWBV-UHFFFAOYSA-N NC(CCC(=O)NC(CS)C(=O)NCC(=O)O)C(=O)O Chemical compound NC(CCC(=O)NC(CS)C(=O)NCC(=O)O)C(=O)O RWSXRVCMGQZWBV-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 229940093761 bile salts Drugs 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229960001927 cetylpyridinium chloride Drugs 0.000 description 1
- NFCRBQADEGXVDL-UHFFFAOYSA-M cetylpyridinium chloride monohydrate Chemical compound O.[Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 NFCRBQADEGXVDL-UHFFFAOYSA-M 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000021472 generally recognized as safe Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- 229940068939 glyceryl monolaurate Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- GPRLSGONYQIRFK-UHFFFAOYSA-N hydron Chemical compound [H+] GPRLSGONYQIRFK-UHFFFAOYSA-N 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- QWPPOHNGKGFGJK-UHFFFAOYSA-N hypochlorous acid Chemical compound ClO QWPPOHNGKGFGJK-UHFFFAOYSA-N 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000002766 immunoenhancing effect Effects 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 150000002484 inorganic compounds Chemical class 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 150000002927 oxygen compounds Chemical class 0.000 description 1
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- CMFNMSMUKZHDEY-UHFFFAOYSA-M peroxynitrite Chemical compound [O-]ON=O CMFNMSMUKZHDEY-UHFFFAOYSA-M 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 238000006894 reductive elimination reaction Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 229940082569 selenite Drugs 0.000 description 1
- MCAHWIHFGHIESP-UHFFFAOYSA-L selenite(2-) Chemical compound [O-][Se]([O-])=O MCAHWIHFGHIESP-UHFFFAOYSA-L 0.000 description 1
- UQDJGEHQDNVPGU-UHFFFAOYSA-N serine phosphoethanolamine Chemical compound [NH3+]CCOP([O-])(=O)OCC([NH3+])C([O-])=O UQDJGEHQDNVPGU-UHFFFAOYSA-N 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- OABYVIYXWMZFFJ-ZUHYDKSRSA-M sodium glycocholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 OABYVIYXWMZFFJ-ZUHYDKSRSA-M 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- JAJWGJBVLPIOOH-IZYKLYLVSA-M sodium taurocholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 JAJWGJBVLPIOOH-IZYKLYLVSA-M 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000006190 sub-lingual tablet Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 235000021241 α-lactalbumin Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Definitions
- This invention relates to nutritional or therapeutic compositions useful for treating mammals to increase their body content of glutathione above a pretreatment level thereby to enhance the immune activity of the treated mammal. More specifically, it relates to compositions containing a selenium compound together with a glutathione precursor which is a mixture of glutamic acid, cystine and glycine.
- Glutathione is a tripeptide and a major reducing agent in the mammalian body. Its chemical structure is:
- ROS reactive oxygen species
- RNS reactive nitrogen species
- Mammalian cells have numerous mechanisms to eliminate these damaging free radicals and reactive species.
- One such mechanism includes the glutathione system, which plays a major role in direct destruction of reactive oxygen compounds and also plays a role in the body's defense against infection.
- glutathione One of the most important contributions of glutathione to mammalian health is its participation in the proper functioning of the immune system to respond to infection or other types of trauma. It is known that weakening of the immune system caused by infection or other traumas occurs concurrently with depletion of glutathione in body tissues. It is known, also, that such weakening can be reversed by replenishing the supply of glutathione. It is believed that glutathione accomplishes its salutary effects by protecting immune cells against the ravages of oxidizing agents and free radicals.
- compositions and methods to aid in elimination of damaging free radicals and reactive oxygen and nitrogen species.
- One possible mechanism for achieving this may be through enhancement of glutathione levels in patients utilizing precursors for glutathione synthesis.
- the mucous membrane is the membrane which lines those body passages which communicate directly or indirectly with the exterior.
- the important parts of the mucous membrane are those portions which line the oral passage, the nose, the anus and the vagina since the compositions are intended for sublingual, buccal, nasal, anal and or vaginal delivery.
- Oral delivery by sublingual or buccal routes is much preferred because of its convenience. Such delivery may be, for example, in the form of pills, lozenges and tablets which may be retained in the mouth until dissolved. In rare instances, parenteral delivery may be utilized, but this is normally not necessary.
- compositions of this invention are:
- the separate components serve as precursors for the metabolic formation of glutathione after they have been transported across the mucous membrane.
- compositions may be used alone but, normally they will be employed in association with one or more non-toxic pharmaceutically acceptable carriers appropriate to the method of administration.
- compositions will be utilized to increase the formation of glutathione and thus to enhance the immune activity of a mammal in need of such treatment.
- the effect of the treatment is such that after the treatment, the mammal will be more resistant to microbial infection or other trauma adversely affecting immune activity than before such treatment.
- compositions are useful to treat a wide variety of diseases associated with the presence of excess free radical or reactive oxygen or nitrogen species. These include, for example, cancer, Alzheimer's disease, arteriosclerosis, rheumatoid arthritis and other autoimmune diseases, cachexia, coronary artery disease, chronic fatigue syndrome, AIDS and others as will be apparent to the skilled artisan.
- compositions described and claimed herein will contain components suitable for the anabolic production of glutathione once they have been transported through the mucous membrane.
- the precursors of glutathione are glutamic acid, cystine and glycine.
- the proposed components are amphoteric and therefore may be employed as non-toxic metal salts or acid addition salts.
- the salts are alkalic or alkaline earth metal salts, preferably sodium, potassium or calcium salts.
- Suitable acid addition salts include salts of hydrochloric, phosphoric and citric acid.
- amino acids may also be employed in the form of certain of their derivatives including esters and anhydrides which before or after transport through the mucous membrane will be modified into the form in which they will be joined together to form glutathione.
- glutamic acid cystine, glycine
- the sulfur containing amino acid in the compositions of this invention is cystine.
- the sulfur containing amino acid moiety in glutathione is cysteine.
- the latter contains a sulfhydryl group. In the former molecule, two cysteine molecules are joined via a disulfide bond.
- cystine is used in the compositions of this invention. Upon reductive cleavage of the disulfide bridge, two molecules of cysteine are formed. Thus each molecule of cystine is capable of forming two molecules, of cysteine, each of which will join with glutamic acid and glycine to form two molecules of glutathione.
- the only component in the novel compositions of this invention which may be toxic is selenium. Accordingly, in providing dosage units for mammalian administration by any selected route, the limiting factor is to avoid treatment either with single or multiple dosage units at such levels that the total delivery of selenium is close to its toxic limit.
- the recommended daily dosage for humans therefore ranges from 10 to 75 ⁇ g per day.
- the range may be generally higher but will, of course, depend upon the animal and its size.
- compositions of this invention for daily delivery and the duration of the period of such delivery will depend upon the professional judgment of the physician or veterinarian in attendance. Numerous factors will be involved in that judgment such as age, body weight, physical condition of the patient or animal and the ailment or disorder being treated.
- Selenium is one of numerous trace metals found in many foods.
- selenium may be employed as one of several non-toxic, water soluble organic or inorganic selenium compounds capable of being absorbed through the mucosal membrane.
- the presently preferred inorganic selenium compounds are aliphatic metal salts containing selenium in the form of selenite or selenate anions.
- organic selenium compounds are more preferred because they are normally less toxic than inorganic compounds.
- Other selenium compounds which may be mentioned by way of example include selenium cystine, selenium methionine, mono- and di-seleno carboxylic acids with about seven to eleven carbon atoms in the chain.
- Seleno Amino acid chelates are also useful. Any of these selenium compounds may be considered for use in the present invention as selenium precursors.
- selenium as employed in the composition be capable of transport through the mucosal membrane of the patient under treatment. For this reason, water insoluble selenium compounds are not generally useful.
- selenium is sometimes used hereinafter to include any of the various water soluble selenium products which can be transported through the mucosal membrane in the practice of this invention. It will be understood, however, that the particular forms of selenium compounds set forth herein are not to be considered limitative. Other selenium compounds, which exhibit the desired activity and are compatible with the other components in the mixture and are non-toxic, can be used in the practice of the invention. Many of them are available commercially.
- the amount of selenium precursor employed in the novel compositions is only enough to provide a catalytic quantity of the element to activate the glutathione system.
- the catalytic quantity of selenium precursor utilized in the compositions of this invention is such that it will produce either in one dosage unit or in multiple dosage units sufficient elemental selenium to promote the production and activation of glutathione. Typically, this will be at or near the recommended daily allowance of selenium for the individual mammal under treatment. This amount will be well below the toxicity limit for elemental selenium.
- a representative range of catalytic quantities of selenium precursors is set forth in the present application in paragraph [0026] on page 6, as shown to be effective based on the age of the individual.
- the presently preferred method of transdermal delivery for the novel compositions is oral, either sublingual or buccal. It is convenient to provide dosage units for such delivery in the form of pills, lozenges or tablets such as gelled tablets which will slowly dissolve in the mouth.
- Nasal delivery will typically be accomplished by sprays or drops. Suppositories will be useful for rectal or vaginal delivery.
- compositions used in the method of the invention comprise a therapeutically effective amount of combined glutamic acid, cystine, glycine and a selenium precursor in a pharmaceutically acceptable carrier.
- pharmaceutically acceptable means one that is generally recognized as safe, approved by a regulatory agency of the federal or a state government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in animals, and more particularly in humans.
- carrier refers to a diluent, adjuvant, excipient, or vehicle with which the active compounds are administered.
- compositions which may be provided in bulk or dosage unit form are prepared in accordance with standard pharmaceutical practice and may contain excipients such as starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, ethanol and the like.
- excipients such as starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, ethanol and the like.
- Sterile liquids such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, and sesame oil may also be useful.
- the composition if desired, can also contain
- Buffering agents are sometimes used in the compositions of the invention to maintain a relatively constant hydrogen ion concentration in the mouth (pH about 7.5) or other point of entry.
- An appropriate buffering agent may be selected from numerous known reagents including, for example phosphate, carbonate and bicarbonate systems.
- Alpha-lactalbumin is useful because of its buffering properties. Additionally, it is non-toxic, water soluble and contains appreciable amounts of the required amino acids.
- compositions may also contain mucous membrane penetration enhancers such as sodium lauryl sulphate, sodium dodecyl sulphate, cationic surfactants such as palmitoyl DL camitine chloride, cetylpyridinium chloride, non-ionic surfactants such as polysorbate 80, polyoxyethylene 9-lauryl either, glyceryl monolaurate, polyoxyalkylenes, polyoxyethylene 20 cetyl ether, lipids such as oleic acid, bile salts such as sodium glycocholate, sodium taurocholate and related compounds.
- mucous membrane penetration enhancers such as sodium lauryl sulphate, sodium dodecyl sulphate, cationic surfactants such as palmitoyl DL camitine chloride, cetylpyridinium chloride, non-ionic surfactants such as polysorbate 80, polyoxyethylene 9-lauryl either, glyceryl monolaurate, polyoxyalkylenes, poly
- compositions of the invention are most conveniently utilized in dosage units for oral administration. They may be used alone but are preferably provided as tablets, suitably sublingual tablets. Such tablets may be prepared in one a day form or for intermittent use throughout the day, for example every three hours.
- the tablets will typically weigh from about 0.5 to 5 grams and will contain a therapeutically effective amount of the essential ingredients together with the selected vehicle.
- “Therapeutically effective” as used herein means the amount of the composition which is sufficient to achieve the desired result, i.e., enhancement of the immune system. It means that the immune system is more effective in combating infection after treatment than it was before treatment.
- compositions of the invention can be provided in a number of different forms and at dosage levels appropriate to the individual mammal being treated.
- tablets, elixers, solutions, emulsions, powders, capsules and other forms can be provided for one a day treatment or successive treatments on the same day for animals or humans whether male or female, whether infant, adolescent or adult.
- the defining feature of this advantage is the amount of selenium precursor utilized since the other components are essentially non-toxic.
- tablets and other forms of the immunoenhancing compositions can be prepared to provide any quantity of elemental selenium from less than 1 ⁇ g to 7.5 ⁇ g.
- a tablet containing 10 ⁇ g of selenium methionine is capable of delivering 4 ⁇ g of elemental selenium
- 7.5 ⁇ g of selenium methionine is capable of delivering 3 ⁇ g of selenium. Tablets may be given several times per day to achieve the desired immune enhancing effect.
- a one a day tablet weighing two grams may contain 200 mg or more of the composition.
- a similar tablet intended to be used every four hours may contain 50 mg to 100 mg or more of the therapeutically effective composition. Equivalent amounts of carrier and active components will be utilized in other compositions designed for other methods of administration.
- EXAMPLE 1 (TABLET) Ingredients: 89 mg cystine 75 mg glycine 147 mg glutamic acid 22.5 ⁇ g polyvinylpyrolidone 61.25 mg lactose 4.5 ml alcohol SD3A-200 proof 9 mg stearic acid 42.3 mg corn starch 10 ⁇ g selenium methionine
- EXAMPLE 2 (TABLET) Ingredients: 178 mg cystine 150 mg glycine 294 mg glutamic acid 5 ⁇ g selenium methionine 126 mg lactose 78 mg potato starch 96 mg ethyl cellulose 54 mg stearic acid
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Inorganic Chemistry (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Biophysics (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- AIDS & HIV (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
Abstract
Nutritional or therapeutic compositions containing glutamic acid, cystine, glycine and a selenium precursor and methods for their utilization to increase glutathione synthesis and thereby enhance the immune system are described.
Description
More than one application for the Reissue of U.S. Pat. No. 6,592,908 has been filed. The reissue applications are the present application and U.S. Ser. No. 11/181,001, filed Jul. 13, 2005, and issued as U.S. Pat. RE 39,734 on Jul. 17, 2007.
This application is a division of U.S. Ser. No. 11/181,001, filed Jul. 13, 2005 and which issued as U.S. Pat. RE 39,734 on Jul. 17, 2007, which is a reissue of U.S. Pat. No. 6,592,908 which issued on Jul. 13, 2005 from U.S. Ser. No. 10/252,957, filed Sep. 23, 2002, the disclosures of which are hereby incorporated by reference herein.
This invention relates to nutritional or therapeutic compositions useful for treating mammals to increase their body content of glutathione above a pretreatment level thereby to enhance the immune activity of the treated mammal. More specifically, it relates to compositions containing a selenium compound together with a glutathione precursor which is a mixture of glutamic acid, cystine and glycine.
Glutathione is a tripeptide and a major reducing agent in the mammalian body. Its chemical structure is:
Its chemical name is glutamyl-cysteinyl-glycine.
Like many other small peptides in the mammalian body, it is not synthesized by procedures involving DNA, RNA and ribosomes. Rather, it is synthesized from the amino acids available in the body by procedures utilizing enzymes and other body components such as adenosine triphosphate as an energy source.
It is generally recognized that many disease processes are attributed to the presence of elevated levels of free radicals, reactive oxygen species (ROS) and reactive nitrogen species (RNS), such as superoxide, hydrogen peroxide, singlet oxygen, peroxynitrite, hydroxyl radicals, hypochlorous acid (and other hypohalous acids) and nitric oxide.
Mammalian cells have numerous mechanisms to eliminate these damaging free radicals and reactive species. One such mechanism includes the glutathione system, which plays a major role in direct destruction of reactive oxygen compounds and also plays a role in the body's defense against infection.
It is known that insufficient levels of glutathione may result in the onset of numerous diseases. Diseases of aging appear to be associated with a drop in glutathione levels. Moreover, since there is no evidence of transport of glutathione into cells, glutathione must be produced intra cellularly.
One of the most important contributions of glutathione to mammalian health is its participation in the proper functioning of the immune system to respond to infection or other types of trauma. It is known that weakening of the immune system caused by infection or other traumas occurs concurrently with depletion of glutathione in body tissues. It is known, also, that such weakening can be reversed by replenishing the supply of glutathione. It is believed that glutathione accomplishes its salutary effects by protecting immune cells against the ravages of oxidizing agents and free radicals.
There is a need for compositions and methods to aid in elimination of damaging free radicals and reactive oxygen and nitrogen species. One possible mechanism for achieving this may be through enhancement of glutathione levels in patients utilizing precursors for glutathione synthesis.
There is some question as to whether orally ingested glutathione is available to enhance the immune system. Since it is a tripeptide, conventional wisdom suggests that it would be hydrolyzed in the intestinal system to release the free amino acids. Even if some of the tripeptide gets through the gastrointestinal wall intact, it is questionable whether it can be absorbed as such into the individual cell, rather than being synthesized intracellularly. Some experts are of the opinion that glutathione resists hydrolysis when taken orally. In any event, it is generally acknowledged that an increase in tissue and cellular concentrations of glutathione facilitates resistance to infective agents by enhancing the immune system.
The mucous membrane is the membrane which lines those body passages which communicate directly or indirectly with the exterior. For purposes of this invention, the important parts of the mucous membrane are those portions which line the oral passage, the nose, the anus and the vagina since the compositions are intended for sublingual, buccal, nasal, anal and or vaginal delivery. Oral delivery by sublingual or buccal routes is much preferred because of its convenience. Such delivery may be, for example, in the form of pills, lozenges and tablets which may be retained in the mouth until dissolved. In rare instances, parenteral delivery may be utilized, but this is normally not necessary.
The essential components of the compositions of this invention are:
1. A selenium precursor together with
2. Glutamic acid, cystine and glycine.
The separate components serve as precursors for the metabolic formation of glutathione after they have been transported across the mucous membrane.
The compositions may be used alone but, normally they will be employed in association with one or more non-toxic pharmaceutically acceptable carriers appropriate to the method of administration.
The compositions will be utilized to increase the formation of glutathione and thus to enhance the immune activity of a mammal in need of such treatment. The effect of the treatment is such that after the treatment, the mammal will be more resistant to microbial infection or other trauma adversely affecting immune activity than before such treatment.
Because of their ability to increase production of glutathione, the compositions are useful to treat a wide variety of diseases associated with the presence of excess free radical or reactive oxygen or nitrogen species. These include, for example, cancer, Alzheimer's disease, arteriosclerosis, rheumatoid arthritis and other autoimmune diseases, cachexia, coronary artery disease, chronic fatigue syndrome, AIDS and others as will be apparent to the skilled artisan.
In accordance with the present invention, the compositions described and claimed herein will contain components suitable for the anabolic production of glutathione once they have been transported through the mucous membrane. As presently conceived, the precursors of glutathione are glutamic acid, cystine and glycine.
It will be appreciated by the skilled artisan that the proposed components are amphoteric and therefore may be employed as non-toxic metal salts or acid addition salts. Typically, the salts are alkalic or alkaline earth metal salts, preferably sodium, potassium or calcium salts. Suitable acid addition salts include salts of hydrochloric, phosphoric and citric acid.
The amino acids may also be employed in the form of certain of their derivatives including esters and anhydrides which before or after transport through the mucous membrane will be modified into the form in which they will be joined together to form glutathione.
All of this will be readily appreciated by those skilled in the art. Accordingly, when the terms glutamic acid, cystine, glycine are employed both in the specification and claims they will be understood to mean not only the products themselves, but also those derivatives which can be converted to a unit of the glutathione molecule.
The sulfur containing amino acid in the compositions of this invention is cystine. The sulfur containing amino acid moiety in glutathione is cysteine. The latter contains a sulfhydryl group. In the former molecule, two cysteine molecules are joined via a disulfide bond.
However, it is not possible to utilize cysteine in compositions for mammals because it is somewhat toxic. Accordingly, in the compositions of this invention, cystine is used. Upon reductive cleavage of the disulfide bridge, two molecules of cysteine are formed. Thus each molecule of cystine is capable of forming two molecules, of cysteine, each of which will join with glutamic acid and glycine to form two molecules of glutathione.
Of course all amino acids employed in this invention, except glycine which does not form optical isomers, are in the natural or L-form.
Although wide variations are possible, it will be apparent that the optimum ratio of glutamic acid to cystine to glycine in the novel compositions described herein is 1:0.5: 1. If an excess of any acid is used, it will presumably be of nutritional value or may simply be metabolized.
As will be apparent to the skilled artisan, the only component in the novel compositions of this invention which may be toxic is selenium. Accordingly, in providing dosage units for mammalian administration by any selected route, the limiting factor is to avoid treatment either with single or multiple dosage units at such levels that the total delivery of selenium is close to its toxic limit.
The recommended daily allowances for elemental selenium as reported in The Pharmacological Basis of Therapeutics, Ninth Edition, page 1540, The McGraw-Hill Companies, 1996 are as follows:
Years | ug | |||
Infants | 0.0-0.5 | 10 | ||
0.5-1.0 | 15 | |||
Children | 1-3 | 20 | ||
4-6 | 20 | |||
7-10 | 30 | |||
Males | 11-14 | 40 | ||
15-18 | 50 | |||
19-24 | 70 | |||
25-50 | 70 | |||
51+ | 70 | |||
Females | 11-14 | 45 | ||
15-18 | 50 | |||
19-24 | 55 | |||
25-50 | 55 | |||
50+ | 55 | |||
Pregnant | — | 65 | ||
Lactating | 1st six months | 75 | ||
2nd six months | 75 | |||
The recommended daily dosage for humans therefore ranges from 10 to 75 μg per day. For animals the range may be generally higher but will, of course, depend upon the animal and its size.
The precise amount of the therapeutically useful compositions of this invention for daily delivery and the duration of the period of such delivery will depend upon the professional judgment of the physician or veterinarian in attendance. Numerous factors will be involved in that judgment such as age, body weight, physical condition of the patient or animal and the ailment or disorder being treated.
Selenium is one of numerous trace metals found in many foods. In the compositions of this invention, selenium may be employed as one of several non-toxic, water soluble organic or inorganic selenium compounds capable of being absorbed through the mucosal membrane. The presently preferred inorganic selenium compounds are aliphatic metal salts containing selenium in the form of selenite or selenate anions. However, organic selenium compounds are more preferred because they are normally less toxic than inorganic compounds. Other selenium compounds which may be mentioned by way of example include selenium cystine, selenium methionine, mono- and di-seleno carboxylic acids with about seven to eleven carbon atoms in the chain. Seleno Amino acid chelates are also useful. Any of these selenium compounds may be considered for use in the present invention as selenium precursors.
It is important for the practice of this invention that the selenium as employed in the composition be capable of transport through the mucosal membrane of the patient under treatment. For this reason, water insoluble selenium compounds are not generally useful.
For convenience, the term “selenium” is sometimes used hereinafter to include any of the various water soluble selenium products which can be transported through the mucosal membrane in the practice of this invention. It will be understood, however, that the particular forms of selenium compounds set forth herein are not to be considered limitative. Other selenium compounds, which exhibit the desired activity and are compatible with the other components in the mixture and are non-toxic, can be used in the practice of the invention. Many of them are available commercially.
In fact, the amount of selenium precursor employed in the novel compositions is only enough to provide a catalytic quantity of the element to activate the glutathione system. The catalytic quantity of selenium precursor utilized in the compositions of this invention is such that it will produce either in one dosage unit or in multiple dosage units sufficient elemental selenium to promote the production and activation of glutathione. Typically, this will be at or near the recommended daily allowance of selenium for the individual mammal under treatment. This amount will be well below the toxicity limit for elemental selenium. By way of non-limiting examples, a representative range of catalytic quantities of selenium precursors is set forth in the present application in paragraph [0026] on page 6, as shown to be effective based on the age of the individual.
As indicated above, the presently preferred method of transdermal delivery for the novel compositions is oral, either sublingual or buccal. It is convenient to provide dosage units for such delivery in the form of pills, lozenges or tablets such as gelled tablets which will slowly dissolve in the mouth.
Nasal delivery will typically be accomplished by sprays or drops. Suppositories will be useful for rectal or vaginal delivery.
This invention provides pharmaceutical compositions used in the method of the invention. Such compositions comprise a therapeutically effective amount of combined glutamic acid, cystine, glycine and a selenium precursor in a pharmaceutically acceptable carrier. In a particular embodiment, the term “pharmaceutically acceptable” means one that is generally recognized as safe, approved by a regulatory agency of the federal or a state government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in animals, and more particularly in humans. The term “carrier” refers to a diluent, adjuvant, excipient, or vehicle with which the active compounds are administered.
The compositions which may be provided in bulk or dosage unit form are prepared in accordance with standard pharmaceutical practice and may contain excipients such as starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, ethanol and the like. Sterile liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, and sesame oil may also be useful. The composition, if desired, can also contain minor amounts of wetting or emulsifying agents, coloring agents or buffering agents.
Buffering agents are sometimes used in the compositions of the invention to maintain a relatively constant hydrogen ion concentration in the mouth (pH about 7.5) or other point of entry. An appropriate buffering agent may be selected from numerous known reagents including, for example phosphate, carbonate and bicarbonate systems. Alpha-lactalbumin is useful because of its buffering properties. Additionally, it is non-toxic, water soluble and contains appreciable amounts of the required amino acids.
The compositions may also contain mucous membrane penetration enhancers such as sodium lauryl sulphate, sodium dodecyl sulphate, cationic surfactants such as palmitoyl DL camitine chloride, cetylpyridinium chloride, non-ionic surfactants such as polysorbate 80, polyoxyethylene 9-lauryl either, glyceryl monolaurate, polyoxyalkylenes, polyoxyethylene 20 cetyl ether, lipids such as oleic acid, bile salts such as sodium glycocholate, sodium taurocholate and related compounds.
Examples of these suitable carriers are described in Remington's Pharmaceutical Sciences, Nineteenth Edition (1990), Mack Publishing Company, Easton, Pa. in Handbook of Pharmaceutical Excipients, published by The American Pharmaceutical Association and The Pharmaceutical Society of Great Britain (1986) and the Handbook of Water-Soluble Gums and Resins, ed. By R. L. Davidson, McGraw-Hill Book Co., New York, N.Y. (1980). Compositions and methods of manufacturing compositions capable of absorption through the mucosal tissues are taught in U.S. Pat. No. 5,288,497. These publications are incorporated by reference herein in their entirety. They can be readily employed by the skilled artisan to devise methods of delivery other than those specifically described in this disclosure.
The compositions of the invention are most conveniently utilized in dosage units for oral administration. They may be used alone but are preferably provided as tablets, suitably sublingual tablets. Such tablets may be prepared in one a day form or for intermittent use throughout the day, for example every three hours.
The tablets will typically weigh from about 0.5 to 5 grams and will contain a therapeutically effective amount of the essential ingredients together with the selected vehicle. “Therapeutically effective” as used herein means the amount of the composition which is sufficient to achieve the desired result, i.e., enhancement of the immune system. It means that the immune system is more effective in combating infection after treatment than it was before treatment.
A particular advantage of the compositions of the invention is that they can be provided in a number of different forms and at dosage levels appropriate to the individual mammal being treated. For example, tablets, elixers, solutions, emulsions, powders, capsules and other forms can be provided for one a day treatment or successive treatments on the same day for animals or humans whether male or female, whether infant, adolescent or adult. The defining feature of this advantage is the amount of selenium precursor utilized since the other components are essentially non-toxic.
Referring to the table above, tablets and other forms of the immunoenhancing compositions can be prepared to provide any quantity of elemental selenium from less than 1 μg to 7.5 μg. For example, a tablet containing 10 μg of selenium methionine is capable of delivering 4 μg of elemental selenium, and 7.5 μg of selenium methionine is capable of delivering 3 μg of selenium. Tablets may be given several times per day to achieve the desired immune enhancing effect.
A one a day tablet weighing two grams may contain 200 mg or more of the composition. A similar tablet intended to be used every four hours may contain 50 mg to 100 mg or more of the therapeutically effective composition. Equivalent amounts of carrier and active components will be utilized in other compositions designed for other methods of administration.
The following examples are given by way of illustration only and are not to be considered a limitation since many apparent variations are possible without departing from the spirit or scope of the invention.
EXAMPLE 1 (TABLET) |
Ingredients: |
89 | mg | cystine |
75 | mg | glycine |
147 | mg | glutamic acid |
22.5 | μg | polyvinylpyrolidone |
61.25 | mg | lactose |
4.5 | ml | alcohol SD3A-200 proof |
9 | mg | stearic acid |
42.3 | mg | corn starch |
10 | μg | selenium methionine |
Blend the cystine, glycine, glutamic acid, polyvinylpyrrolidone and lactose together and pass through a 40 mesh screen. Add the alcohol slowly and knead well. Screen the wet mesh through a 4 mesh screen. Dry the granulation at 50 degrees centigrade for 10 hours. Pass the mixture of stearic acid, corn starch and selenium compound through a 60 mesh screen and tumble with the granulation until all the ingredients are well mixed. Compress using a 7/16 inch standard concave punch.
EXAMPLE 2 (TABLET) |
Ingredients: |
178 | mg | cystine |
150 | mg | glycine |
294 | mg | glutamic acid |
5 | μg | selenium methionine |
126 | mg | lactose |
78 | mg | potato starch |
96 | mg | ethyl cellulose |
54 | mg | stearic acid |
Thoroughly mix the ingredients in a blender, dry, put through a 12 mesh screen and compress into tablet using a 13/32 inch concave punch.
Claims (29)
1. A nutritional or therapeutic composition useful for treatment of mammals to enhance immune activity comprising as the essential active ingredients a catalytic quantity of a selenium source together with a glutathione precursor which is a mixture of glutamic acid, cystine and glycine in a molar ratio of about 1:0.5:1, the amount of glutathione precursor being effective to increase the content of glutathione in the body tissue of the mammal above that of a pretreatment level thereby to enhance immune activity.
2. A composition of claim 1 in dosage unit form.
3. A composition of claim 1 in bulk form.
4. A composition of claim 2 , wherein the dosage unit is for oral administration.
5. A composition of claim 2 , wherein the dosage unit is for nasal administration.
6. A composition of claim 4 , wherein the dosage unit is for sublingual administration.
7. A composition of claim 4 , wherein the dosage unit is for buccal administration.
8. A composition of claim 1 , useful for treating a human.
9. A composition of claim 1 useful for treating an animal.
10. A method of treating a mammal to increase the tissue glutathione concentration in said mammal which comprises treating a mammal in need of such treatment with a therapeutically effective amount of a composition comprising as the essential active ingredients a catalytic quantity of a selenium source together with a glutathione precursor which is a mixture of glutamic acid, cystine and glycine in a molar ratio of about 1:0.5:1.
11. A method of claim 10 , wherein the mammal is an animal.
12. A method of claim 10 , wherein the mammal is a human.
13. A composition for increasing the level of glutathione in a mammal consisting of:
(A) an anabolic precursor of glutathione, consisting of glutamic acid or a salt, an ester, or an anhydride thereof, cystine or a salt, an ester, or an anhydride thereof and glycine or a salt, an ester, or an anhydride thereof, which collectively convert to glutathione; and
(B) a source of selenium, in an amount that is non-toxic to the mammal on a daily total unit dosage delivery basis; wherein said source of selenium is selenium methionine, selenium cystine, a mono-seleno carboxylic acid with seven to eleven carbon atoms in a chain, or a di-seleno carboxylic acid with seven to eleven carbon atoms in a chain.
14. The composition according to claim 13 in unit dosage form.
15. The composition according to claim 13 in bulk form.
16. The composition according to claim 14 wherein the dosage unit is for oral administration.
17. The composition according to claim 14 wherein the dosage unit is for nasal administration.
18. The composition according to claim 14 wherein the dosage unit is for sublingual administration.
19. The composition according to claim 14 wherein the dosage unit is for buccal administration.
20. The composition according to claim 14 wherein the dosage unit is for anal or vaginal administration.
21. The composition of claim 13 wherein the mammal is a human.
22. The composition of claim 13 wherein one or more of said glutamic acid, cystine, and glycine are in the form of a salt, an ester, or an anhydride thereof.
23. The composition of claim 13 wherein the glutamic acid is in the form of a salt, an ester, or an anhydride thereof.
24. The composition of claim 13 wherein the cystine is in the form of a salt, an ester, or an anhydride thereof.
25. The composition of claim 13 wherein the glycine is in the form of a salt, an ester or an anhydride thereof.
26. The composition according to claim 13, wherein the source of selenium is in a mucosal-membrane transportable form.
27. A method of increasing the level of glutathione in a mammal comprising administering to said mammal an effective amount of a composition consisting of:
(A) an anabolic precursor of glutathione, consisting of glutamic acid or a salt, an ester, or an anhydride thereof, cystine or a salt, an ester, or an anhydride thereof and glycine or a salt, an ester or an anhydride thereof, which collectively convert to glutathione; and
(B) a source of selenium, in an amount that is non-toxic to the mammal on a daily total unit dosage delivery basis; wherein said source of selenium is selenium methionine, selenium cystine, a mono-seleno carboxylic acid with seven to eleven carbon atoms in a chain, or a di-seleno carboxylic acid with seven to eleven carbon atoms in a chain.
28. The method of claim 27 wherein cystine converts to cysteine in the intracellular formation of glutathione.
29. The method of claim 27 wherein the source of selenium provides a unit dosage on an elemental basis of from 1 μg to 7.5 μg of selenium.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/371,804 USRE42645E1 (en) | 2002-09-23 | 2006-03-09 | Nutritional or therapeutic compositions and methods to increase bodily glutathione levels |
US13/184,041 US20120029082A1 (en) | 2002-09-23 | 2011-07-15 | Nutritional or therapeutic compositions to increase bodily glutathione levels |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/252,957 US6592908B1 (en) | 2002-09-23 | 2002-09-23 | Nutritional or therapeutic compositions |
US11/181,001 USRE39734E1 (en) | 2002-09-23 | 2005-07-13 | Nutritional or therapeutic compositions to increase bodily glutathione levels |
US11/371,804 USRE42645E1 (en) | 2002-09-23 | 2006-03-09 | Nutritional or therapeutic compositions and methods to increase bodily glutathione levels |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/252,957 Reissue US6592908B1 (en) | 2002-09-23 | 2002-09-23 | Nutritional or therapeutic compositions |
US11/181,001 Division USRE39734E1 (en) | 2002-09-23 | 2005-07-13 | Nutritional or therapeutic compositions to increase bodily glutathione levels |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/184,041 Continuation US20120029082A1 (en) | 2002-09-23 | 2011-07-15 | Nutritional or therapeutic compositions to increase bodily glutathione levels |
Publications (1)
Publication Number | Publication Date |
---|---|
USRE42645E1 true USRE42645E1 (en) | 2011-08-23 |
Family
ID=22958261
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/252,957 Ceased US6592908B1 (en) | 2002-09-23 | 2002-09-23 | Nutritional or therapeutic compositions |
US11/181,001 Expired - Lifetime USRE39734E1 (en) | 2002-09-23 | 2005-07-13 | Nutritional or therapeutic compositions to increase bodily glutathione levels |
US11/371,804 Expired - Lifetime USRE42645E1 (en) | 2002-09-23 | 2006-03-09 | Nutritional or therapeutic compositions and methods to increase bodily glutathione levels |
US13/184,041 Abandoned US20120029082A1 (en) | 2002-09-23 | 2011-07-15 | Nutritional or therapeutic compositions to increase bodily glutathione levels |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/252,957 Ceased US6592908B1 (en) | 2002-09-23 | 2002-09-23 | Nutritional or therapeutic compositions |
US11/181,001 Expired - Lifetime USRE39734E1 (en) | 2002-09-23 | 2005-07-13 | Nutritional or therapeutic compositions to increase bodily glutathione levels |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/184,041 Abandoned US20120029082A1 (en) | 2002-09-23 | 2011-07-15 | Nutritional or therapeutic compositions to increase bodily glutathione levels |
Country Status (8)
Country | Link |
---|---|
US (4) | US6592908B1 (en) |
EP (2) | EP3431080A1 (en) |
JP (2) | JP5601745B2 (en) |
AU (2) | AU2003253884A1 (en) |
BR (2) | BRPI0314666B8 (en) |
CA (1) | CA2539567C (en) |
MX (1) | MXPA05003227A (en) |
WO (1) | WO2004026289A1 (en) |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103478718A (en) * | 2013-09-27 | 2014-01-01 | 美国东方生物技术(香港)有限公司 | Functional food for improving concentration of glutathione in human body and preparation method of functional food |
CN103535721A (en) * | 2013-09-27 | 2014-01-29 | 美国东方生物技术(香港)有限公司 | Composition for improving glutathione concentration in human body and preparation method and application thereof |
WO2016033183A1 (en) | 2014-08-29 | 2016-03-03 | Crum Albert B | A method for side effect reduction in the use of statins via physiologically synthesized glutathione |
WO2018114749A1 (en) | 2016-12-21 | 2018-06-28 | Unilever Plc | Personal care compositions with cystine |
WO2018114745A1 (en) | 2016-12-21 | 2018-06-28 | Unilever Plc | Personal care compositions comprising poorly soluble compounds |
US11077039B2 (en) | 2016-12-21 | 2021-08-03 | Conopco, Inc. | Topical skin lightening additive and composition with amino acids and nicotinamide compounds |
WO2021219375A1 (en) | 2020-04-28 | 2021-11-04 | Unilever Ip Holdings B.V. | Process of making n,n'-diacetyl-l-cystine |
WO2021219378A1 (en) | 2020-04-28 | 2021-11-04 | Unilever Ip Holdings B.V. | Stabilized cosmetic compositions with n, n'-di-acetyl cystine |
WO2021219377A1 (en) | 2020-04-28 | 2021-11-04 | Unilever Ip Holdings B.V. | Process of making n,n-diacetyl-l-cystine disodium salt from cystine and acetyl chloride in methanol in the presence of sodium hydroxide |
WO2021219376A1 (en) | 2020-04-28 | 2021-11-04 | Unilever Ip Holdings B.V. | Personal care compositions with enhanced solubility actives |
US11260005B2 (en) | 2016-12-21 | 2022-03-01 | Conopco, Inc. | Personal care compositions with glutathione precursor comprising 4-substituted resorcinols and amino acids |
WO2024052700A1 (en) | 2022-09-08 | 2024-03-14 | The Proimmune Company, Llc | Compositions to increase glutathione levels and processes for making the same |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1656152A1 (en) * | 2003-06-06 | 2006-05-17 | Pro-Health, Inc. | Composition and method for treating upper abdominal pain and cramping |
WO2005007223A2 (en) * | 2003-07-16 | 2005-01-27 | Sasha John | Programmable medical drug delivery systems and methods for delivery of multiple fluids and concentrations |
US20050271726A1 (en) * | 2004-06-02 | 2005-12-08 | Albert Crum | Immune enhancing compositions and methods of use thereof |
FR2879074B1 (en) * | 2004-12-15 | 2007-08-03 | Adisseo France Sas Soc Par Act | PELLETS OF ACTIVE HYDROPHILIC PRINCIPLE |
US20080095826A1 (en) * | 2006-10-24 | 2008-04-24 | Hisayuki Uneyama | Method of Increasing Peripheral Blood Lymphocytes |
CA3081693C (en) * | 2014-10-09 | 2022-01-11 | Albert Crum | Protective metallothionein analog compounds, their compositions and use thereof in the reduction of heavy metal toxicity |
AU2017234662A1 (en) * | 2016-03-14 | 2018-10-04 | Mitogenetics, Llc | Materials and methods for treating hypoxic conditions |
JP7084567B2 (en) * | 2016-12-21 | 2022-06-15 | ユニリーバー・アイピー・ホールディングス・ベスローテン・ヴェンノーツハップ | Personal care composition comprising a glutathione precursor comprising nicotinamide and an amino acid |
EP3773422B1 (en) | 2018-05-23 | 2021-11-10 | Unilever IP Holdings B.V. | Nanoemulsions and a method for making the same |
WO2022145325A1 (en) * | 2020-12-28 | 2022-07-07 | サンスター スイス エスエー | Composition for oral cavity |
US20240108696A1 (en) * | 2022-09-21 | 2024-04-04 | Lile Method Research, Llc | Compositions and methods for improving vaccine therapy |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2292522A (en) | 1994-08-22 | 1996-02-28 | Gitta Carmen Conway | Multi-vitamin preparation for treatment of the immune system |
US5550146A (en) | 1992-12-23 | 1996-08-27 | Abbott Laboratories | Medical foods for the nutritional support of infant/toddler metabolic diseases |
US5576351A (en) * | 1989-12-29 | 1996-11-19 | Mcgaw, Inc. | Use of arginine as an immunostimulator |
RU2096034C1 (en) * | 1994-11-30 | 1997-11-20 | Общество с ограниченной ответственностью "Медицинский научно-производственный комплекс "БИОТИКИ" | Pharmaceutical composition inducing glutathione biosynthesis, glutathione transferase activity and showing antitoxic, radioprotective and antihypoxic action and methods of treatment, prophylaxis and protection using thereof |
US5719133A (en) | 1994-09-21 | 1998-02-17 | Novartis Nutrition Ag | Adolescent dietary composition |
WO1998015614A1 (en) | 1996-10-10 | 1998-04-16 | Life Technologies, Inc. | Animal cell culture media comprising plant-derived nutrients |
US20010048948A1 (en) | 1998-06-10 | 2001-12-06 | Crum Albert B. | Prophylactic and therapeutic nutritional supplement for creation/maintenance of health-protective intestinal microflora and enhancement of the immune system |
US6495170B1 (en) | 2000-08-16 | 2002-12-17 | N. V. Nutricia | Method of increasing the presence of glutathione in cells |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5288497A (en) | 1985-05-01 | 1994-02-22 | The University Of Utah | Compositions of oral dissolvable medicaments |
JPH0667833B2 (en) * | 1985-11-28 | 1994-08-31 | 雪印乳業株式会社 | Enteral nutrition |
US4885157A (en) * | 1987-02-13 | 1989-12-05 | Fiaschetti Mary G | Dermal cosmetic composition and applications therefor |
CA1333471C (en) * | 1988-04-29 | 1994-12-13 | Gustavo Bounous | Whey protein concentrate as food supplement |
US5888552A (en) * | 1988-04-29 | 1999-03-30 | Immunotec Research Corporation Ltd. | Anti-cancer therapeutic compositions containing whey protein concentrate |
JP3013871B2 (en) * | 1993-10-02 | 2000-02-28 | 日本水産株式会社 | Method for activating immune activity of marine cultured fish |
JPH1149696A (en) * | 1997-03-21 | 1999-02-23 | Shiseido Co Ltd | Immune activator for preventing hypofunction of ultra-violet skin immunofunction |
JPH11292737A (en) * | 1998-02-16 | 1999-10-26 | Shiseido Co Ltd | Immunopotentiation agent |
JP2000245358A (en) * | 1999-02-25 | 2000-09-12 | Kohjin Co Ltd | Production diet and raising method for salmon and/or trout |
AU6768200A (en) | 1999-08-11 | 2001-03-05 | Proimmune Company L.L.C., The | Nutritious compositions and food components |
GB0009056D0 (en) * | 2000-04-12 | 2000-05-31 | Nestle Sa | Composition comprising free amino acids |
-
2002
- 2002-09-23 US US10/252,957 patent/US6592908B1/en not_active Ceased
-
2003
- 2003-07-11 BR BRPI0314666A patent/BRPI0314666B8/en active IP Right Grant
- 2003-07-11 CA CA2539567A patent/CA2539567C/en not_active Expired - Lifetime
- 2003-07-11 EP EP18193031.4A patent/EP3431080A1/en not_active Withdrawn
- 2003-07-11 WO PCT/US2003/021739 patent/WO2004026289A1/en active Application Filing
- 2003-07-11 AU AU2003253884A patent/AU2003253884A1/en not_active Abandoned
- 2003-07-11 JP JP2004537620A patent/JP5601745B2/en not_active Expired - Lifetime
- 2003-07-11 MX MXPA05003227A patent/MXPA05003227A/en active IP Right Grant
- 2003-07-11 BR BRPI0314666A patent/BRPI0314666B1/en active IP Right Grant
- 2003-07-11 EP EP03797809.5A patent/EP1556023B1/en not_active Expired - Lifetime
-
2005
- 2005-07-13 US US11/181,001 patent/USRE39734E1/en not_active Expired - Lifetime
-
2006
- 2006-03-09 US US11/371,804 patent/USRE42645E1/en not_active Expired - Lifetime
-
2010
- 2010-03-23 AU AU2010201136A patent/AU2010201136B2/en not_active Expired
-
2011
- 2011-07-15 US US13/184,041 patent/US20120029082A1/en not_active Abandoned
- 2011-09-22 JP JP2011207922A patent/JP5846822B2/en not_active Expired - Lifetime
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5576351A (en) * | 1989-12-29 | 1996-11-19 | Mcgaw, Inc. | Use of arginine as an immunostimulator |
US5550146A (en) | 1992-12-23 | 1996-08-27 | Abbott Laboratories | Medical foods for the nutritional support of infant/toddler metabolic diseases |
GB2292522A (en) | 1994-08-22 | 1996-02-28 | Gitta Carmen Conway | Multi-vitamin preparation for treatment of the immune system |
US5719133A (en) | 1994-09-21 | 1998-02-17 | Novartis Nutrition Ag | Adolescent dietary composition |
RU2096034C1 (en) * | 1994-11-30 | 1997-11-20 | Общество с ограниченной ответственностью "Медицинский научно-производственный комплекс "БИОТИКИ" | Pharmaceutical composition inducing glutathione biosynthesis, glutathione transferase activity and showing antitoxic, radioprotective and antihypoxic action and methods of treatment, prophylaxis and protection using thereof |
WO1998015614A1 (en) | 1996-10-10 | 1998-04-16 | Life Technologies, Inc. | Animal cell culture media comprising plant-derived nutrients |
US20010048948A1 (en) | 1998-06-10 | 2001-12-06 | Crum Albert B. | Prophylactic and therapeutic nutritional supplement for creation/maintenance of health-protective intestinal microflora and enhancement of the immune system |
US6495170B1 (en) | 2000-08-16 | 2002-12-17 | N. V. Nutricia | Method of increasing the presence of glutathione in cells |
Non-Patent Citations (79)
Title |
---|
Basic Medical Biochemistry, Velker, J. (ed.), Williams & Wilkins, Baltimore, 1996, pp. 598-601. * |
BIOSIS abstract 2001:509422 (2001). * |
Considine, D.M. et al. Van Nostrand's Scientific Encyclopedia, 7th ed., Van Nostrand Reinhold, New York, pp. 128-129 (1989). * |
Dale, W.M., et al. A study of the irradiation of catalase by ionizing radiations in the presence of cysteine, crystine and glutathione. Biochem J (1950) 62(1):50-7. |
Derwent abstract 1998-320409; abstracting RU 2096034 (1997). * |
Guoyao Wu, et al; Gutathione Metabolism . . . for Health; American Society for Nutritional Sciences; 2004; pp. 489-492. |
Hideyo Sato et al; Distribution of Cystine/Glutamate . . . Mouse Brain; The Journal of Neuroscience, Sep. 15, 2002; 22(18):8028-8033. |
Hutchin, M.E., et al. "Microbiological determination of cystine, systeine, and glutathione in plasma." J Biol Chem (1950) 185(2):839-43. |
Juan R. Vina, et al. "Maintenance of GSH Content in Primary Astrocyte Cultures Under Oxidative Stress Conditions" Biochemical Society Transactions (1993) 21:845. |
Kenji Miura, et al; Cystine Uptake and . . . Oxidative Stress; The American Physiological Society; 1992; pp. C50-C58. |
Martindale The Extra Pharmacopoeia, 30th ed., The Pharmaceutical Press, London, 1993, p. 1047. * |
Meier, T., et al. "Promotion of Cyst(e)ine Uptake" Methods Enzymol. (1995) vol. 252, pp. 103-112. |
PubMed Abstract 10 Curi, R., et al. "Glutamine-dependent changes in gene expression and protein activity." Cell Biochem Funct. (2005) 23(2):77-84. |
PubMed Abstract 123. Wang et al. "Hepatic Export of Glutathione and Uptake of Constituent Amino Acids, Glutamate and Cysteine, in Broilers in Vivo." Poult Sci. (1998) Oct.; 77 (10):1556-1564. |
PubMed Abstract 124 Wernerman, J., et al. "Glutathione status in critically-ill patients: possibility of modulation by antioxidants." Proc Nutr Soc. (1999) 58(3):677-80. |
PubMed Abstract 137. Tachi et al. "High Concentration of Glucose Causes Impairment of the Function of the Glutathione Redox Cycle in Human Vascular Smooth Muscle Cells." FEBS Lett. (1998) Jan. 2; 421 (1):19-22. |
PubMed Abstract 139. Kranich et al. "Utilization of Cysteine and Cysteine Precursors for the Synthesis of Glutathione in Astroglial Cultures: Preference for Cystine." Glia. (1998) Jan.: 22 (1):11-18. |
PubMed Abstract 141. Lu, SC. "Regulation of Hepatic Glutathione Synthesis." Semin Liver Dis. (1998) 18(4):331-343. |
PubMed Abstract 143. Knickelbein et al. "Characterization of Multiple Cysteine and Cystine Transporters in Rat Alveolar Type II Cells." Am J Physiol. (1997) Dec.; 273(6 Pt 1):L1147-1155. |
PubMed Abstract 15 Soh, H., et al. "Glutamine regulates amino acid transport and glutathione levels in a human neuroblastoma cell line." Pediatr Surg Int. (2005) 21(1):29-33. |
PubMed Abstract 150. Sayato et al. "Selenium Methylation and Toxicity Mechanism of Selenocystine." Yakugaku Zasshi (1997) Nov.; 117 (10-11):665-672. |
PubMed Abstract 159. van Klaveren et al. "Cellular Glutathione Turnover in Vitro, with Emphasis on Type II Pneumocytes." Eur Respir J. (1997) Jun.; 10(6):1392-1400. |
PubMed Abstract 160. Froissard et al. "Role of Glutathione Metabolism in the Glutamate-Induced Programmed Cell Death of Neuronal-Like PC12 Cells." Eur J Pharmacol. (1997) May 12;326 (1):93-99. |
PubMed Abstract 167. Ochi, T. "Arsenic Compound-Induced Increases in Glutathione Levels in Cultured Chinese Hamster V79 Cells and Mechanisms Associated with Changes in Gamma-Glutamylcysteine Synthetase Activity, Cystine Uptake and Utilization of Cysteine." Arch Toxicol. (1997); 71(12):730-740. |
PubMed Abstract 172. Kranich et al. "Different Preferences in the Utilization of Amino Acids for Glutathione Synthesis in Cultured Neurons and Astroglial Cells Derived from Rat Brain." Neurosci Lett. (1996) Nov. 29; 219 (3):211-214. |
PubMed Abstract 173. Pan et al. "Increased Uptake of L-Cysteine and L-Cystine by Nerve Growth Factor in Rat Pheochromocytoma Cells." Brian Res. (1996) Nov. 18; 740 (1-2):21-26. |
PubMed Abstract 177. Mills et al. "Differential Distribution of Free and Bound Glutathione and Cyst(e)ine in Human Blood." Biochem Pharmacol. (1996) Aug. 9; 52(3):401-406. |
PubMed Abstract 180 Denno, R., et al. "Glutamine-enriched total parenteral nutrition enhances plasma glutathione in the resting state." J Surg Res. (1996) 61(1):35-8. |
PubMed Abstract 186. Sagara et al. "Glutathione Efflux from Cultures Astrocytes." J Neurochem. (1996) May; 66 (5):1876-1881. |
PubMed Abstract 187. Rathbun et al. "Prevention of Acetaminophen- and Naphthalene-Induced Cataract and Glutathione Loss by CySSME." Invest Ophthalmol Vis Sci. (1996) Apr.; 37 (5):923-929. |
PubMed Abstract 187. Rathbun et al. "Prevention of Acetaminophen- and Naphthalene-Induced Cataract and Glutathione Loss by CySSME." Invest Ophthalmol Vis Sci. (1996) Apr.; 37 (5):923-929. |
PubMed Abstract 193. Deneke et al. "Mechanisms of Use of Extracellular Glutathione by Lung Epithelial Cells and Pulmonary Artery Endothelial Cells." Am J Respir Cell Mol Biol. (1995) Jun.; 12 (6):662-668. |
PubMed Abstract 193. Deneke et al. "Mechanisms of Use of Extracellular Glutathione by Lung Epithelial Cells and Pulmonary Artery Endothelial Cells." Am J Respir Cell Mol Biol. (1995) Jun.; 12 (6):662-668. |
PubMed Abstract 195. O'Connor et al. "Biosynthesis and Maintenance of GSH in Primary Astrocyte Cultures: Role of L-Cystine and Ascorbate." Brain Res. (1995) May 22; 680 (1-2):157-163. |
PubMed Abstract 214. Cotgreave et al. "A Role for Gamma-Glutamyl Transpeptidase in the Transport of Cystine into Human Endothelial Cells: Relationship to Intracellular Glutathione." Biochim Biophys Acta. (1994) Jul. 21; 1222 (3):375-382. |
PubMed Abstract 23 Alhamdan, A.A. "The effect of dietary supplementation of N-acetyl-L-cysteine on glutathione concentration and lipid peroxidation in cigarette smoke-exposed rats fed a low-protein diet." Saudi Med J. (2005) 26(2):208-14. |
PubMed Abstract 231. Sagara et al. "Maintenance of Neuronal Glutathione by Glial Cells." J Neurochem. (1993) Nov.; 61 (5):1672-1676. |
PubMed Abstract 232. Sagara et al. "Cystine Uptake and Glutathione Level in Fetal Brain Cells in Primary Culture and in Suspension." J Neurochem. (1993) Nov.; 61 (5):1667-1671. |
PubMed Abstract 238. Vina et al. "Maintenance of GSH Content in Primary Astrocyte Cultures Under Oxidative Stress Conditions." Biochem Soc Trans. (1993) May; 21 (2):84S. |
PubMed Abstract 255. Phelps et al. "Elevation of Glutathione Levels in Bovine Pulmonary Artery Endothelial Cells by N-Acetylcysteine." Am J Respir Cell Mol Biol. (1992) Sep.; 7 (3):293-299. |
PubMed Abstract 265. Deneke et al. "Endothelial Cell Cystine Uptake and Glutathione Increase with N,N-bis(2-chloroethyl)-N-Nitrosourea Exposure." Am J Physiol. (1992) Mar.; 262 (3 Pt 1):L301-304. |
PubMed Abstract 266. Brandi et al. "Differential Effect of the Amino Acid Cystine in Cultured Mammalian and Bacterial Cells Exposed to Oxidative Stress." Mutat Res. (1992) Mar.; 281 (3):157-161. |
PubMed Abstract 271. Droge et al. "Modulation of Lymphocyte Functions and Immune Responses by Cysteine and Cysteine Derivatives." Am J Med. (1991) Sep. 30; 91 (3C):140S-144S. |
PubMed Abstract 292. Atzori et al. "Growth-Associated Modifications of Low-Molecular-Weight Thiols and Protein Sulfhydryls in Human Bronchial Fibroblasts." J Cell Physiol. (1990) Apr.; 143 (1):165-171. |
PubMed Abstract 298. Bannai et al. "Induction of Cystine Transport Activity in Human Fibroblasts by Oxygen." J Biol Chem. (1989) Nov. 5; 264 (31):18480-18484. |
PubMed Abstract 309 Wagner, B. "Glutathione in Tetrahymena thermophila." J Protozool (1989) 36(1):92-5. |
PubMed Abstract 314 Siegel, D.A., et al. "Effect of pairing in vitro on the glutathione level of male Schistosoma mansoni." J Parasitol (1988) 74(4):524-31. |
PubMed Abstract 316 Nygaard, M.E., et al. "Sulfhydryl-related reduction of the mitotic inhibition and cell inactivation induced by pyrimidine analogs." Anticancer Drug Des. (1988) 3(1):15-24. |
PubMed Abstract 320 Ishii, T., et al. "Regulation of glutathione levels in mouse spleen lymphocytes by transport of cysteine." J. Cell Physiol. (1987) 133(2):330-6. |
PubMed Abstract 369 Mickelson, M.N., et al. "Cystine antagonism of the antibacterial action of lactoperoxidase-thiocyanate-hydrogen peroxide on Streptococcus agalactiae." Appl Environ Microbiol (1984) 47(2):338-42. |
PubMed Abstract 372 Orrenius, S., et al. "Turnover and functions of glutathione studied with isolated hepatic and renal cells." Fed Proc (1983) 42(15):3177-88. |
PubMed Abstract 379 Ohmori, H., et al. "Mechanism of augmentation of the antibody response in vitro by 2-mercaptoethanol in murine lymphocytes. II. A major role of the mixed disulfide between 2-mercaptoethanol and cysteine." Cell Immunol (1983) 79(1):173-85. |
PubMed Abstract 38 Aliciguzel, Y., et al. "N-acetyl cysteine, L-cysteine, and beta-mercaptoethanol augment selenium-glutathione peroxidase activity in glucose-6-phosphate dehydrogenase-deficient human erythrocytes." Clin Exp Med (2004) 4(1):50-5. |
PubMed Abstract 391 Bannai, S., et al. "Adaptive enhancement of cystine and glutamate uptake in human diploid fibroblasts in culture." Biochim Biophys Acta (1982) 721(1):1-10. |
PubMed Abstract 394 Bannai, S., et al. "Transport of cystine and cysteine and cell growth in cultured human diploid fibroblasts: effect of glutamate and homocysteate." J Cell Physiol (1982) 112(2):265-72. |
PubMed Abstract 405 Moldeus, P., et al. "Turnover of cellular glutathione in isolated rat-kidney cells. Role of cystine and methionine." Eur J Biochem (1981) 116(1):13-6. |
PubMed Abstract 406 Ishii, T., et al. "Mechanism of growth promotion of mouse lymphoma L1210 cells in vitro by feeder layer or 2-mercaptoethanol." J Cell Physiol (1981) 107(2):283-93. |
PubMed Abstract 422 Rafter, G.W., et al. "Disulfide-disulfide interchange catalyzed by a liver supernatant enzyme." Biochim Biophys Acta (1979) 567(1):18-23. |
PubMed Abstract 44 Evans, M.E., et al. "Glutamine prevents cytokine-induced apoptosis in human colonic epithelial cells." J Nutr. (2003) 133(10):3065-71. |
PubMed Abstract 440 Tuttle, S., et al. "Radiation-sensitive tyrosine phosphorylation of cellular proteins: sensitive to changes in GSH content induced by pretreatment with N-acetyl-L-cysteine or L-buthionine-S,R-sulfoximine." Int J Radiat Oncol Biol Phys. (1998) 42(4):833-8. |
PubMed Abstract 446 Thompson, G. A., et al. "Utilization of L-cystine by the gamma-glutamyl transpeptidase-gamma-glutamyl cyclotransferase pathway." Proc Nati Acad Sci U S A (1975) 72(6):1985-8. |
PubMed Abstract 549 Hou, Y., et al. "Seleno compounds and glutathione peroxidase catalyzed decomposition of S-nitrosothiols." Biochem Biophys Res Commun. (1996) 228(1):88-93. |
PubMed Abstract 572 Holleschau, A.M., et al. "An HPLC radiotracer method for assessing the ability of L-cysteine prodrugs to maintain glutathione levels in the cultured rat lens." Curr Eye Res. (1996) 15(5):501-10. |
PubMed Abstract 61. Powell et al. "Restoration of Glutathione Levels in Vascular Smooth Muscle Cells Exposed to High Glucose Conditions." Free Radic Biol Med. (2001) Nov. 15; 31 (10):1149-1155. |
PubMed Abstract 70 Valencia, E., et al. "Impact of oral L-glutamine on glutathione, glutamine, and glutamate blood levels in volunteers." Nutrition (2002) 18(5):367-70. |
PubMed Abstract 74 Yildiz, D. "Inhibition of tumor growth by replacing glutathione with N-acetyl-L-cysteine." Med Hypotheses (2004) 63(1):80-2. |
PubMed Abstract 84. Bender et al. "Characterization of Cystine Uptake in Cultured Astrocytes." Neurochem Int. (2000) Aug.-Sep.; 37 (2-3):269-276. |
PubMed Abstract 9 Hammarqvist, F., et al. "Free amino acid and glutathione concentrations in muscle during short-term starvation and refeeding." Clin Nutr. (2005) 24(2):236-43. |
PubMed Abstract 98 Wu, G., et al. "Glutathione metabolism and its implications for health." J Nutr. (2004) 134(3):489-92. |
PubMed Abstract of Deneke SM, et al . Am J Respir Cell Mol Biol. 1995 Jun.; 12(6);662-8. |
PubMed Abstract Phelps, DT., et al. Am J Respir Cell Mol Biol. 1992 Sep. 7(3):293-9. |
Ralf Dringen, et al; Glutathione Contents as as Indicator . . . Cultures; Journal of Neurochemistry; vol. 67, No. 4; May 19, 1996; pp. 1375-1382. |
Schulman, J., et al, "Cystine, Cysteine, and Glutathione Metabolism in Normal and Cystinotic Fibroblasts in Vitro, and in Cultured Normal Amniotic Fluid Cells" Clin. Chim. Acta (1972) 37(53-58). |
Shelly C. Lu, Current Topics in Cellular Regulation (2000) 36:95-116. |
Shelly C. Lu, The FASEB Journal (1999) 13:1169-1183. |
Shiro Bannai; Exchange Of Cystine . . . Fibroblast; The Journal of Biological Chemistry; vol. 261; No. 5; Feb. 15, 1986; pp. 2256-2263. |
Thomas Meier, et al. Methods in Enzymology (1995) 252:103-112. |
Veber, D.F., et al. "Synthesis of alpha-methyl-DL-g-glutathione." J Med Chm (1967) 10(5):968-9. |
Veber, D.G., e al. "Synthesis of alpha-methyl-DL-glutathione." J. Med. Chm. (1967) 10(5): 968-9. |
Cited By (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103478718A (en) * | 2013-09-27 | 2014-01-01 | 美国东方生物技术(香港)有限公司 | Functional food for improving concentration of glutathione in human body and preparation method of functional food |
CN103535721A (en) * | 2013-09-27 | 2014-01-29 | 美国东方生物技术(香港)有限公司 | Composition for improving glutathione concentration in human body and preparation method and application thereof |
CN103478718B (en) * | 2013-09-27 | 2015-10-28 | 美国东方生物技术(香港)有限公司 | Improve functional food of glutathione concentration in human body and preparation method thereof |
CN103535721B (en) * | 2013-09-27 | 2016-04-06 | 美国东方生物技术(香港)有限公司 | Improve composition and method of making the same and the application of glutathione concentration in human body |
WO2016033183A1 (en) | 2014-08-29 | 2016-03-03 | Crum Albert B | A method for side effect reduction in the use of statins via physiologically synthesized glutathione |
US11337908B2 (en) | 2016-12-21 | 2022-05-24 | Conopco, Inc. | Personal care compositions with cystine |
WO2018114749A1 (en) | 2016-12-21 | 2018-06-28 | Unilever Plc | Personal care compositions with cystine |
US10751267B2 (en) | 2016-12-21 | 2020-08-25 | Conopco, Inc. | Personal care compositions comprising poorly soluble compounds |
US10980718B2 (en) | 2016-12-21 | 2021-04-20 | Conopco, Inc. | Personal care compositions comprising poorly soluble compounds |
US11077039B2 (en) | 2016-12-21 | 2021-08-03 | Conopco, Inc. | Topical skin lightening additive and composition with amino acids and nicotinamide compounds |
US11759412B2 (en) | 2016-12-21 | 2023-09-19 | Conopco, Inc. | Personal care compositions with glutathione precursor comprising 4-substituted resorcinols and amino acids |
US11666519B2 (en) | 2016-12-21 | 2023-06-06 | Conopco, Inc. | Personal care compositions with cystine |
US11596586B2 (en) | 2016-12-21 | 2023-03-07 | Conopco, Inc. | Personal care compositions with glutathione precursor comprising 4-substituted resorcinols and amino acids |
WO2018114745A1 (en) | 2016-12-21 | 2018-06-28 | Unilever Plc | Personal care compositions comprising poorly soluble compounds |
US11260005B2 (en) | 2016-12-21 | 2022-03-01 | Conopco, Inc. | Personal care compositions with glutathione precursor comprising 4-substituted resorcinols and amino acids |
WO2021219376A1 (en) | 2020-04-28 | 2021-11-04 | Unilever Ip Holdings B.V. | Personal care compositions with enhanced solubility actives |
WO2021219377A1 (en) | 2020-04-28 | 2021-11-04 | Unilever Ip Holdings B.V. | Process of making n,n-diacetyl-l-cystine disodium salt from cystine and acetyl chloride in methanol in the presence of sodium hydroxide |
WO2021219378A1 (en) | 2020-04-28 | 2021-11-04 | Unilever Ip Holdings B.V. | Stabilized cosmetic compositions with n, n'-di-acetyl cystine |
WO2021219375A1 (en) | 2020-04-28 | 2021-11-04 | Unilever Ip Holdings B.V. | Process of making n,n'-diacetyl-l-cystine |
WO2024052700A1 (en) | 2022-09-08 | 2024-03-14 | The Proimmune Company, Llc | Compositions to increase glutathione levels and processes for making the same |
Also Published As
Publication number | Publication date |
---|---|
JP2012017336A (en) | 2012-01-26 |
CA2539567C (en) | 2013-09-24 |
USRE39734E1 (en) | 2007-07-17 |
BRPI0314666B1 (en) | 2015-12-29 |
WO2004026289A1 (en) | 2004-04-01 |
JP5846822B2 (en) | 2016-01-20 |
AU2010201136B2 (en) | 2013-01-24 |
US20120029082A1 (en) | 2012-02-02 |
BR0314666A (en) | 2005-08-02 |
EP1556023A1 (en) | 2005-07-27 |
JP5601745B2 (en) | 2014-10-08 |
EP1556023A4 (en) | 2010-06-02 |
EP3431080A1 (en) | 2019-01-23 |
MXPA05003227A (en) | 2005-08-18 |
JP2006502182A (en) | 2006-01-19 |
AU2003253884A1 (en) | 2004-04-08 |
US6592908B1 (en) | 2003-07-15 |
AU2010201136A1 (en) | 2010-04-15 |
BRPI0314666B8 (en) | 2022-11-22 |
EP1556023B1 (en) | 2018-10-17 |
CA2539567A1 (en) | 2004-04-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
USRE42645E1 (en) | Nutritional or therapeutic compositions and methods to increase bodily glutathione levels | |
US5597585A (en) | Vitamin/mineral composition | |
US20080081796A1 (en) | Treatment of mucositis | |
JP2009242413A (en) | Medicine based on amino acid | |
US4438144A (en) | Amino acid preparation and therapy for treatment of stress and injury | |
GB2374008A (en) | Compositions including copper and their uses | |
JPH04327537A (en) | Method of insuring sufficient intracellular glutathione in tissue | |
US5747459A (en) | Method for insuring adequate intracellular glutathione in tissue | |
Mitch et al. | Effects of oral neomycin and kanamycin in chronic uremic patients: II. Nitrogen balance | |
JPH08503964A (en) | Dietary hypocholesterolemic composition | |
Freeman-Narrod et al. | Chronic toxicity of methotrexate in rats: partial to complete protection of the liver by choline: brief communication | |
CA2193396A1 (en) | A pharmaceutical composition for the prevention and/or treatment of viral infections and optionally inflammations as well as a method for the treatment thereof | |
US6605306B1 (en) | Food supplement formulation | |
US7166582B2 (en) | Antiallergic composition | |
DE69714821T2 (en) | PHARMACOLOGICAL COMBINATION OF N-ACETYLCYSTEINE AND LEVULOSE FOR THE PREVENTION OF CELL DEATH AND RELATED DISEASES | |
WO2022224776A1 (en) | Lipid decrease promoter | |
JP7291380B2 (en) | Immediate-acting agent for oral mucosa administration for runny nose or nasal congestion | |
JPH0710770A (en) | Amino acid transfusion solution | |
US6277883B1 (en) | Method of treating male impotence by enhancing the effectiveness of the human immune system | |
US20070141176A1 (en) | Elemental sulfur as an oral or parentral medical product | |
Hall et al. | FATAL FAMILIAL FETAL HYPERKERATOSIS | |
Gray | Pharmacology: Vitamins: Nutrients, Food Additives, or Medications Vitamin C | |
PL108619B1 (en) | Method of producing new aminoacid derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FPAY | Fee payment |
Year of fee payment: 12 |
|
SULP | Surcharge for late payment |
Year of fee payment: 11 |
|
AS | Assignment |
Owner name: THE PROIMMUNE COMPANY, LLC, NEW YORK Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CRUM, ALBERT, DR.;REEL/FRAME:060428/0947 Effective date: 20220315 |